CRTH2 Antagonist Programme

Oxagen’s Lead Programme – CRTH2 antagonists for Asthma, allergy and inflammatory Disease.

Oxagen has identified a number of potent antagonists of the CRTH2 receptor which are highly selective small molecular weight compounds with a range of physical properties enabling multiple administration routes to treat a range of allergic and inflammatory diseases in man. To date preclinical activity has been demonstrated in a number of models of asthma and allergic and inflammatory diseases.

The lead molecule OC000459 has completed Phase IIa proof-of-concept clinical studies and is currently being evaluated in a Phase IIb dose range-finding study. OC000459 has demonstrated an excellent safety profile in over 300 subjects and has shown efficacy in both asthma and allergic rhinoconjunctivitis. Other molecules in this and other series, all covered by Oxagen’s patent estate are being developed for a range of other therapeutic indications including rhinitis, atopic dermatitis and allergic conjunctivitis.

Click here for further information on Oxagen’s CRTH2 programme.